{
  "nctrialId": "HC-1677",
  "title": "A  Double-Blind, Active-Controlled  Study of BRE-701 (selective estrogen receptor modulator) in Patients With Pancreatic Cancer",
  "officialTitle": "A  Double-Blind, Active-Controlled  Study of BRE-701 (selective estrogen receptor modulator) in Patients With Pancreatic Cancer",
  "sponsor": "Canadian Blood Services",
  "indication": "Pancreatic Cancer",
  "phase": "Phase 1",
  "fileName": "HC-1677.json",
  "fileSize": 595802,
  "date": "2025-03-01",
  "completionDate": "2026-05-08",
  "drugName": "BRE-701 (selective estrogen receptor modulator)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Withdrawn",
  "description": "This is a  double-blind, active-controlled  study designed to evaluate the efficacy and safety of BRE-701 (selective estrogen receptor modulator) in patients with Pancreatic Cancer. The study will enroll approximately 365 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 26-84 years\n- Confirmed diagnosis of Pancreatic Cancer\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n- Measurable disease per RECIST v1.1\n- Prior treatment with standard therapy\n- Life expectancy \u22653 months\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment\n- Brain metastases unless treated and stable\n- Prior treatment with similar mechanism of action\n- Other active malignancy requiring treatment",
  "csr_id": "HC-1677"
}